Weigao II
The status, timeline and source of this project. A free account opens every field.
Source: International Finance Corporation (IFC)
Weigao and its subsidiaries (together “the Group”) is the leading manufacturer of single-use medical devices in China. The Group has a wide range of products, which includes: (a) consumables (infusion set, syringes, medical needle, blood bags, pre-filled syringes, blood sampling products, and other consumables); (b) orthopedic materials (such as steel plates and screws); and (c) blood purification
- Status
- Closed
- Sector
- Water Supply and Storage, Commercial, Residential, Manufacturing (Industrial), Steel, Government, Hospital, Metal
- Location
- China
- Updated
- 22 Jul 2026
- Source
- International Finance Corporation (IFC)
ConstructChat
Ask ConstructChat about Weigao II
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | completed |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Weigao and its subsidiaries (together “the Group”) is the leading manufacturer of single-use medical devices in China. The Group has a wide range of products, which includes: (a) consumables (infusion set, syringes, medical needle, blood bags, pre-filled syringes, blood sampling products, and other consumables); (b) orthopedic materials (such as steel plates and screws); and (c) blood purification consumables (such as dialysis equipment). Weigao is listed on the Hong Kong Stock Exchange.The blood purification business is based in one of Weigao’s subsidiaries – Weigao Blood. Weigao Blood covers a wide range of blood purification medical devices including hemodialysis machines, high and low flux polysulfone membrane dialyzers and tubing system. In addition to manufacturing, Weigao blood also has a healthcare holding company known as Shandong Weigao Medical Holding Company Limited which runs hemodialysis centers. All the dialysis centers have facilities where patients receive treatment for about 4 hours twice or thrice a week. No patients stay overnight at these centers. The proposed IFC investment is a debt investment (A loan), proceeds of which will be used towards financing the expansion of Weigao’s blood purification business under its subsidiary, Weigao Blood, through: (i) the expansion of its manufacturing capacity for dialyzer, tubing and related consumables; and (ii) the opening additional company-operated standalone dialysis centers (together, the “Project”). The expected size of the dialysis centers would be between 10 to 100 treatment beds. |
Original sector | G-FA - Pharmaceuticals and Medicine |
Location
Country | China |
Source
Source | International Finance Corporation (IFC) |
URL |
More Details
Record type | Project |
Sector | Water Supply and Storage, Commercial, Residential, Manufacturing (Industrial), Steel, Government, Hospital, Metal |
Article published date | 2025-09-10 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Water Supply and Storage projects in China
- Yangjiang Nuclear Power Plant Guangdong Province
- Shidao Bay Nuclear Power Plant
- Sanmen Nuclear Power Plant Zhejiang Province
- Baihetan Hydropower Project China
- The Ertan China Hydropower Plant Project
- Yebatan Hydropower Project
- Qinshan Nuclear Power Plant Haiyan County Zhejiang
- Lingao Nuclear Power Station Guangdong
